Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of the Efficacy and Safety of CMA-676 as Single Agent Treatment of Patients With Acute Myeloid Leukemia (AML) in First Relapse

NCT00003131 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00003131
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003131 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of the Efficacy and Safety of CMA-676 as Single Agent Treatment of Patients With Acute Myeloid Leukemia (AML) in First Relapse
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
February 28, 1997
Completion date
February 28, 2002
Enrollment
55 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia